PortfoliosLab logoPortfoliosLab logo
ORANY vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ORANY vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Orange S.A (ORANY) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ORANY achieves a 16.98% return, which is significantly higher than AZN's -5.80% return. Over the past 10 years, ORANY has underperformed AZN with an annualized return of 8.27%, while AZN has yielded a comparatively higher 12.78% annualized return.


ORANY

1D
-1.54%
1M
5.07%
6M
5.59%
YTD
16.98%
1Y
24.99%
3Y*
26.53%
5Y*
18.49%
10Y*
8.27%
ALL TIME*
3.44%

AZN

1D
-0.99%
1M
-13.07%
6M
-6.66%
YTD
-5.80%
1Y
17.91%
3Y*
8.37%
5Y*
10.71%
10Y*
12.78%
ALL TIME*
12.63%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$431.89M$497.68M$403.88M
$2.51M$3.29M$3.20M

ORANY vs. AZN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ORANY
Orange S.A
16.98%79.38%-7.70%23.28%0.00%-3.50%-14.18%-5.31%-2.39%20.06%
AZN
AstraZeneca PLC
-5.80%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%

Correlation

The correlation between ORANY and AZN is 0.21, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.21

Correlation (3Y)
Balances recent behavior with more history.

0.22

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.26

Correlation (10Y)
Provides a long-term view across more market conditions.

0.25

Correlation (All Time)
Calculated using the full available price history since Oct 20, 1997

0.32

The correlation between ORANY and AZN shifts across timeframes, from 0.21 (1 year) to 0.32 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ORANY:

$50.55B

AZN:

$131.47B

EPS

ORANY:

€1.75

AZN:

$13.34

PE Ratio

ORANY:

9.42

AZN:

12.71

PEG Ratio

ORANY:

0.00

AZN:

0.02

PS Ratio

ORANY:

0.67

AZN:

2.16

PB Ratio

ORANY:

1.53

AZN:

2.63

Total Revenue (TTM)

ORANY:

€81.61B

AZN:

$61.18B

Gross Profit (TTM)

ORANY:

€18.06B

AZN:

$48.56B

EBITDA (TTM)

ORANY:

€26.58B

AZN:

$20.49B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ORANY vs. AZN — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ORANY
ORANY Risk / Return Rank: 7979
Overall Rank
ORANY Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
ORANY Sortino Ratio Rank: 7878
Sortino Ratio Rank
ORANY Omega Ratio Rank: 7676
Omega Ratio Rank
ORANY Calmar Ratio Rank: 7979
Calmar Ratio Rank
ORANY Martin Ratio Rank: 8181
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 6666
Overall Rank
AZN Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 6666
Sortino Ratio Rank
AZN Omega Ratio Rank: 6262
Omega Ratio Rank
AZN Calmar Ratio Rank: 6565
Calmar Ratio Rank
AZN Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ORANY vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Orange S.A (ORANY) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ORANYAZNDifference
Sharpe ratioReturn per unit of total volatility

+0.53

Sortino ratioReturn per unit of downside risk

+0.66

Omega ratioGain probability vs. loss probability

1.23

1.15

+0.09

Calmar ratioReturn relative to maximum drawdown

2.02

0.92

+1.10

Martin ratioReturn relative to average drawdown

5.55

2.43

+3.12

ORANY vs. AZN - Sharpe Ratio Comparison

The current ORANY Sharpe Ratio is 1.26, which is higher than the AZN Sharpe Ratio of 0.73. The chart below compares the historical Sharpe Ratios of ORANY and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ORANY vs. AZN - Drawdown Comparison

The maximum ORANY drawdown since its inception was -96.42%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for ORANY and AZN.


Loading charts...

Drawdown Indicators


ORANYAZNDifference

Max Drawdown

Largest peak-to-trough decline

-96.42%

-48.94%

-47.48%

Max Drawdown (1Y)

Largest decline over 1 year

-15.33%

-21.08%

+5.75%

Max Drawdown (3Y)

Largest decline over 3 years

-17.72%

-27.87%

+10.15%

Max Drawdown (5Y)

Largest decline over 5 years

-27.73%

-27.87%

+0.14%

Max Drawdown (10Y)

Largest decline over 10 years

-38.92%

-27.87%

-11.05%

Current Drawdown

Current decline from peak

-57.09%

-18.62%

-38.47%

Average Drawdown

Average peak-to-trough decline

-73.54%

-11.39%

-62.15%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.58%

7.99%

-2.41%

Volatility

ORANY vs. AZN - Volatility Comparison

The current volatility for Orange S.A (ORANY) is 7.68%, while AstraZeneca PLC (AZN) has a volatility of 11.83%. This indicates that ORANY experiences smaller price fluctuations and is considered to be less risky than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ORANYAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.68%

11.83%

-4.15%

Volatility (6M)

Calculated over the trailing 6-month period

19.16%

19.94%

-0.78%

Volatility (1Y)

Calculated over the trailing 1-year period

24.65%

27.24%

-2.59%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

20.05%

24.51%

-4.46%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

20.79%

24.96%

-4.17%

Dividends

ORANY vs. AZN - Dividend Comparison

ORANY's dividend yield for the trailing twelve months is around 4.62%, more than AZN's 3.14% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
3.14%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
ORANY
Orange S.A
4.62%5.15%7.84%6.64%7.42%8.95%5.84%5.33%5.03%4.28%4.41%4.04%

Financials

ORANY vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Orange S.A and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

ORANY vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Orange S.A and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

ORANY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Orange S.A reported a gross profit of 7.47B and revenue of 21.36B. Therefore, the gross margin over that period was 35.0%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, AstraZeneca PLC reported a gross profit of 11.18B and revenue of 15.19B. Therefore, the gross margin over that period was 73.6%.

ORANY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Orange S.A reported an operating income of 6.35B and revenue of 21.36B, resulting in an operating margin of 29.7%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, AstraZeneca PLC reported an operating income of 3.07B and revenue of 15.19B, resulting in an operating margin of 20.2%.

ORANY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Orange S.A reported a net income of 3.63B and revenue of 21.36B, resulting in a net margin of 17.0%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, AstraZeneca PLC reported a net income of 2.48B and revenue of 15.19B, resulting in a net margin of 16.3%.


Frequently Asked Questions


ORANY and AZN have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AZN has higher volatility (11.83%) compared to ORANY (7.68%). In terms of maximum drawdown, ORANY dropped -96.42% vs AZN's -48.94%.

ORANY currently has the higher Sharpe Ratio (1.26 vs 0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ORANY and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer